Company intelligence / Profile preview
Delta4
Vienna, Vienna, Austriadelta4.ai ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Delta4 leverages its proprietary Hyper-C AI platform to identify novel therapeutic indications for existing drugs with known safety profiles. The company has demonstrated success in uncovering new potential uses for compounds such as Iguratimod, advancing some candidates into pre-clinical testing—particularly in rare/orphan disease areas like terminal kidney failure. Their approach aims to accelerate clinical development by de-risking candidate selection through computational modeling and big data analytics.
- Therapeutic areas
- ImmunologyRare DiseasesNephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Delta4.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delta4.